📢 Big news! Prostate Cancer and Prostatic Diseases has reached a new Impact Factor of 5.8! A strong recognition of the quality and relevance of our research in the field of urology. Thank you to our authors, reviewers, and readers! #Urology #ProstateCancer #ImpactFactor

@cosimodenunzio sums us tips/tricks in POST BPH surgery journey in recovery -particularly with “FUN” #OAB @SIU_urology #SIU2025 . Takes time (3-6months) for bladder recovery and poses challenge in initial weeks for pt, uro and nursing team. Multimodal care with meds, pelvic PT

AI in BPH surgery? ✅ A new ML model predicts incontinence with 86.2% accuracy! ⚡️Thulium laser 👴 Age, IPSS, prostate size & more 💡 Best performer: XGBoost 🚨 High PPV = fewer surprises for patients 🔗 Link: https://t.co/OgPEt0oplD

🧬 Hispanic men are under-tested for prostate cancer genetics due to language, literacy & trust barriers 😔 But the interest is there! 🙋‍♂️ Time for culturally sensitive outreach to close the gap 🔍 📎 [ https://t.co/Y2aForg8uG]

🧠 New insights for GBM with #ProstateCancer: 📉 EBRT = less climacturia, ED with condoms, penile changes 🔥 But more anodyspareunia vs RP 💡 EBRT may suit insertive, RP for receptive partners [ https://t.co/Sz4dXkkAP8]

🤖🔍 Machine learning is changing the game in #ProstateCancer detection! With MRI, it delivers 92% sensitivity & 90% specificity for benign vs malignant PCa 💪 A promising future for csPCa diagnosis too! 🔗 https://t.co/LxdXz8toNe

👨‍⚕️🔬 First-ever report on remote radical prostatectomy using 5G & robotic tech! ✅ Safe ✅ Effective ✅ Comparable to local surgery The future is NOW! 🚀 👇 Full study: [ https://t.co/zbl4xb83Ri]

👨‍⚕️ VA data reveals: In de novo mCSPC, first-line ADT + ARPI = ✅ Better overall survival ✅ Slower mCRPC progression ✅ Stronger PSA response Time to intensify! 💪 🔗 https://t.co/GI0xDpepSu

💡 Real-time MR navigation boosts outcomes in #RARP for high-risk #ProstateCancer! 🧠 Better nerve-sparing 💪 Faster continence & potency recovery ⚔️ Lower positive surgical margins Same cancer control ✅ 🔗 https://t.co/YDArd74zBL

🎯 PSMA PET + MRI = smarter decisions in PCa surgery! Side-specific EPE prediction just got sharper 🔍 SUVmax, GGG & tumor burden lead the way 🚀 📊 New model > old MRI-only version 🔗 [ https://t.co/6XGZtoThc1]

🎙️ New episode out now! We talk with Prof. @LambAlastair about the TRANSLATE trial – a milestone study reshaping how we approach prostate cancer management. 👉 Don’t miss the insights: https://t.co/TXm7maltSN #ProstateCancer #ClinicalTrials #UroPodcast

Honored to publish in European Urology 🚀 From an idea by Prof. @cosimodenunzio and a stellar team, we went beyond systematically reviewing MISTs for BPO—by proposing a bold definition of “success” and testing it across all domains for each procedure 👉 https://t.co/v8XenW6wUJ

🚀 Bp-MRI could be the future of prostate imaging! 📈 Sensitivity: ~0.89 vs 0.90 for Mp-MRI 📉 Higher specificity 💉 Contrast-free, patient-friendly #ProstateCancer #Radiology 🔗 [ https://t.co/veme4Nkiu0]

🚀 New RCT comparing M-HoLEP vs ThuFLEP for BPH treatment! 💡 Both safe & effective at 12 months, but M-HoLEP shined with: ⏱ Faster enucleation 💉 Less hematuria 🏥 Shorter hospital stay & earlier catheter removal 🔗 [ https://t.co/M8mE6LaI82]

#ThrowbackThursday 🚀 3-year results are in! The 2nd-gen iTIND device offers durable relief for men with BPO-related LUTS — no late complications, no sexual side effects, and sustained symptom improvement 💪🍃 🔗 https://t.co/3eU56ioSHU

1️⃣ 📊 PSA density + mpMRI: New study finds lesion location matters! For PI-RADS 3: 🔹 PZ lesions → risk rises at PSAd ≥0.05 🔹 TZ lesions → risk rises at PSAd ≥0.13 For PI-RADS ≥4 ➡️ risk stays high regardless. 🩺 Read more: [ https://t.co/MAVA2QzTHb]

📢 New data for high-risk prostate cancer 🚀 In a STAMPEDE-like cohort staged with PSMA PET-CT, hypofractionated RT + long-term ADT (no abiraterone) achieved: ✅ 6-yr MFS: 80.7% ✅ PCSS: 95.8% ✅ OS: 94.4% Strong local control can rival systemic intensification in select cases

💡 In advanced #ProstateCancer, 1st-line ADT often needs intensification. 📉 But VA data show racial disparities: Black, Hispanic & others less likely to get follow-up treatment than Whites. 🧪 More research needed to understand why. 🔗 https://t.co/E8RmzqZ1p5

#ThrowbackThursday 📉 Men on active surveillance with a negative first follow-up biopsy have lower risk of progression & treatment! 💡 This global study suggests we could reduce biopsy frequency in this group to avoid unnecessary procedures. 🔗 [ https://t.co/PEcbzkWC0s]

💡 First clinical look at FloStent™ for #BPH: ✔ 100% implant success ✔ Significant symptom relief ✔ Safe removal even after 1 year Could this be the future of #LUTS management? 🔗 [ https://t.co/SpHrVP80zk]

📉 TURP still dominates, but laser tech is catching up fast in #ProstateCancer care! 🔦 HoLEP & ThuLEP = fewer complications, less bleeding, shorter ICU time. 📊 Safer & smarter choices? More here 👉 https://t.co/vuVdiPjEOk